Please assess the completion status of the following clinical trial:

Trial Title: Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed SCLC~* Extensive stage~* No prior chemotherapy~* WHO PS 0-3~* Adequate organ function (liver, kidney)~* Adequate hematology (bone marrow)~* Informed consent~Exclusion Criteria:~* PS 4~* Inadequate organ function~* Uncontrolled infection~* Concomitant major medical contraindications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Topotecan + cisplatin
- B (Type: ACTIVE_COMPARATOR): Etoposide + carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).